Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Company Overview - Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [4] - The company's lead development candidate, paltusotine, is an investigational, first-in-class, oral, once-daily somatostatin receptor type 2 (SST2) agonist currently in Phase 3 clinical development for acromegaly and in Phase 2 for carcinoid syndrome associated with neuroendocrine tumors [4] - Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, which is completing Phase 2 clinical studies for congenital adrenal hyperplasia and Cushing's disease [4] - All drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, addressing various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, diabetes, obesity, and GPCR-targeted oncology indications [4] Upcoming Events - Company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, at 5:35 p.m. Eastern Time [2] - Additionally, management will participate in the Cantor Global Healthcare Conference on September 18, 2024, at 8:35 a.m. Eastern Time [2] - Live and archived webcasts of these events will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website [2]